GURU.Markets stock price, segment price, and overall market index valuation
The company's share price RedHill Biopharma
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. Its share price reflects the commercial success of its drugs and the progress of its new developments in clinical trials.
Share prices of companies in the market segment - Pharma git
RedHill Biopharma is an Israeli pharmaceutical company focused on drugs for the treatment of gastrointestinal diseases and infections. We have classified it in the Pharma: Gastrointestinal category. The chart below shows how investors value companies with a diversified portfolio of commercial products.
Broad Market Index - GURU.Markets
RedHill Biopharma is an Israeli biopharmaceutical company focused on developing drugs for the treatment of gastrointestinal diseases. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
RDHL - Daily change in the company's share price RedHill Biopharma
RedHill Biopharma Ltd.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures its sensitivity to drug sales and clinical trial news.
Daily change in the price of a set of shares in a market segment - Pharma git
RedHill Biopharma specializes in gastrointestinal medications, a competitive and volatile segment of the pharmaceutical market. The chart below shows average price fluctuations in this niche, allowing you to compare RDHL's stock performance with other companies in the field.
Daily change in the price of a broad market stock, index - GURU.Markets
RedHill Biopharma is an Israeli biopharmaceutical company specializing in the treatment of gastrointestinal diseases. Its shares are driven by news about sales and the development of new drugs. This specific dynamic contributes to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization RedHill Biopharma
RedHill Biopharma's year-over-year performance tells the story of its transition to the commercial stage. Its market capitalization growth over the past 12 months reflects its success in selling its gastrointestinal and infectious disease medications. Its valuation is a bet on its ability to successfully compete with larger players and grow its market share.
Annual dynamics of market capitalization of the market segment - Pharma git
RedHill Biopharma Ltd. is an Israeli biopharmaceutical company with a diversified portfolio. The chart shows how its commercialization success, clinical trial results, and focus on gastrointestinal diseases influence its volatile performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
RedHill Biopharma, a biopharmaceutical company specializing in gastrointestinal diseases, already has commercial products on the market. Its year-over-year market capitalization reflects not only expectations for future developments but also actual sales volumes, making it more stable than early-stage biotechs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization RedHill Biopharma
RedHill is an Israeli biopharmaceutical company with commercial products. Its monthly performance reflects both sales of its approved drugs and progress in clinical programs. Quarterly revenue reports and trial data are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal tract treatments, including two commercial products. The company's success depends on sales growth and the success of its R&D efforts. The pharmaceutical sector chart will highlight the general trends against which RedHill is commercializing its niche products.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. Its success depends on sales of approved drugs and the results of clinical trials of new candidates. The company's shares can move independently of the market, reacting to sales reports and regulatory news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization RedHill Biopharma
RedHill Biopharma, an Israeli pharmaceutical company focused on gastrointestinal diseases, has several products on the market and in development. Its weekly stock price is a combination of sales reports and clinical trial news, creating a complex news environment.
Weekly dynamics of market capitalization of the market segment - Pharma git
RedHill Biopharma is a biopharmaceutical company specializing in gastrointestinal diseases. It has both commercial products and drugs in development. This chart helps you assess whether sales data or clinical trial news have a greater impact on its stock compared to the sector as a whole.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
RedHill Biopharma is a biopharmaceutical company whose shares fluctuate between phases of clinical trials. This chart clearly demonstrates how independent its performance is from overall stock market trends and driven solely by internal scientific news.
Market capitalization of the company, segment and market as a whole
RDHL - Market capitalization of the company RedHill Biopharma
RedHill Biopharma's market capitalization is a measure of investors' valuation of its portfolio of commercial gastrointestinal drugs. The chart shows how the market values its sales and research programs, including its Crohn's disease drug. Its low valuation reflects its high debt load and competitiveness in the pharmaceutical market.
RDHL - Share of the company's market capitalization RedHill Biopharma within the market segment - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company with a portfolio of commercially available gastrointestinal drugs. Its market share is small, but it enjoys stable revenue. Its market capitalization reflects both sales of its existing products and the potential of its development pipeline.
Market capitalization of the market segment - Pharma git
Below is a chart showing the total value of the entire pharmaceutical sector focused on gastrointestinal diseases. For RedHill Biopharma, with its portfolio of drugs, this line represents a map of unmet needs. Its dynamics demonstrate the size of the market for effective treatments for common digestive disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
RedHill Biopharma is an Israeli company specializing in gastrointestinal medications. Its market capitalization is the valuation of its drug portfolio. Overall, this represents the market share of the digestive tract.
Book value capitalization of the company, segment and market as a whole
RDHL - Book value capitalization of the company RedHill Biopharma
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. Its book value is its financial resources and approved drug portfolio. This is its capital for marketing and further research. How has it changed? The chart below shows this history.
RDHL - Share of the company's book capitalization RedHill Biopharma within the market segment - Pharma git
RedHill Biopharma is a diversified biopharmaceutical company. Its business relies on R&D centers to develop new drugs and a commercial infrastructure to market approved medications. The chart shows its share of physical assets required for the full development and sales cycle.
Market segment balance sheet capitalization - Pharma git
RedHill Biopharma is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. As a commercial company, RedHill invests not only in R&D but also in the infrastructure to market its products.
Book value of all companies included in the broad market index - GURU.Markets
RedHill Biopharma's assets are not its manufacturing plants, but rather a portfolio of approved and marketed gastrointestinal drugs, as well as several candidates in development. Its book value reflects both its commercial infrastructure and the value of its intellectual property.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company with a portfolio of commercial products. Its market capitalization is based on its current sales and late-stage development pipeline, making it less speculative than many biotech companies.
Market to book capitalization ratio in a market segment - Pharma git
RedHill Biopharma is an Israeli pharmaceutical company. Its valuation on this chart is the sum of the valuations of its commercial products and the potential of its clinical-stage developments. Investors weigh current revenue against future expectations.
Market to book capitalization ratio for the market as a whole
RedHill Biopharma is a pharmaceutical company with a portfolio of commercial products and developments. Its valuation is a combination of current sales and future expectations. This chart allows you to assess how the market balances these two factors for specialty pharmaceutical companies compared to the market average.
Debts of the company, segment and market as a whole
RDHL - Company debts RedHill Biopharma
RedHill, an Israeli biopharmaceutical company, is commercializing several drugs. It uses debt financing to support its global sales and marketing efforts, as well as to continue R&D. This chart illustrates the company's financing strategy during the challenging phase of growing revenue from its products.
Market segment debts - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal diseases. The company has both commercial products and a pipeline of developments. This chart shows how it balances marketing expenses for existing drugs with investments in costly clinical trials for new candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio RedHill Biopharma
RedHill Biopharma is an Israeli pharmaceutical company with a portfolio of commercial products for the treatment of gastrointestinal diseases and migraines. Marketing and sales of these drugs, as well as conducting new research, require significant resources. This chart shows how the company uses debt to finance its commercial and research activities.
Market segment debt to market segment book capitalization - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company focused on gastrointestinal treatments. Commercializing its products requires significant expenses. This chart shows how the company finances its sales and marketing. It compares its debt to the market capitalization of the entire pharmaceutical sector.
Debt to book value of all companies in the market
RedHill Biopharma is an Israeli pharmaceutical company focused on gastrointestinal diseases. Drug commercialization and research require significant capital. How heavily does the company rely on debt? This chart of total market debt provides context for assessing its financial strategy and sustainability.
P/E of the company, segment and market as a whole
P/E - RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal diseases. This chart shows how investors value its commercial products and development pipeline. This value is based on sales growth and clinical trial results.
P/E of the market segment - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of gastrointestinal and infectious diseases. This chart illustrates the average valuation in the pharmaceutical sector, where investors evaluate both commercialized products and development potential.
P/E of the market as a whole
RedHill Biopharma is a specialty biopharmaceutical company focused on commercializing drugs for the treatment of gastrointestinal and infectious diseases. This chart reflects the overall sentiment in the pharmaceutical sector. It helps understand what influences RDHL's valuation more: overall market trends or the commercial success of its approved products.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal and infectious disease treatments. This chart shows how investors assess the commercial potential of the company's approved products and the success of its clinical programs, which forms the basis for its profit forecasts.
%20P%2FE%20RedHill%20Biopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-RedHill-Biopharma&v=1772513838064 "Chart of the company's future (projected) P/E RedHill Biopharma")
Future (projected) P/E of the market segment - Pharma git
RedHill Biopharma is a specialized biopharmaceutical company focused on gastrointestinal and infectious diseases. The chart reflects future revenue forecasts for the sector. It helps understand the market's confidence in the commercial success of its currently approved drugs and the potential of drugs in development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772513838077 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal tract treatments. The company has both commercial products and development pipelines. This market sentiment chart helps assess how investors balance current revenues and future growth potential in the pharmaceutical industry.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513838099 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company that commercializes drugs for the treatment of gastrointestinal diseases and infections. Profits are driven by sales volumes of its products. This chart shows the financial performance of a company that has successfully completed the process from development to commercialization.
Profit of companies in the market segment - Pharma git
RedHill Biopharma is a specialty biopharmaceutical company focused on the treatment of gastrointestinal and infectious diseases. Its portfolio includes both commercial and developmental products. This chart shows overall profitability in the gastroenterology sector, where a diversified approach combining sales and R&D can ensure sustainable growth.
Overall market profit
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal diseases. The company's success depends on sales of its commercial products and clinical trial results. Demand for drugs for these conditions is stable and independent of economic cycles, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company RedHill Biopharma
RedHill Biopharma is a specialty pharmaceutical company focused on gastrointestinal diseases. Future profits depend on sales of its commercial products and the success of its clinical development. This chart shows analysts' assessments of its product portfolio and commercial prospects.
%20profit%20of%20the%20company%20RedHill%20Biopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-RedHill-Biopharma&v=1772513838185 "Graph of future (projected) profit of the company RedHill Biopharma")
Future (predicted) profit of companies in the market segment - Pharma git
RedHill Biopharma is a biopharmaceutical company specializing in gastrointestinal diseases. Its portfolio includes both commercialized drugs and late-stage development pipelines. This chart shows revenue expectations for the pharmaceutical sector, providing context for assessing RedHill's product pipeline and its prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772513838203 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal diseases. Its commercial success depends on sales and market acceptance of its products. This economic outlook affects the overall solvency of the healthcare system and the willingness of insurers to cover new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513838206 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - RedHill Biopharma
RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases. Revenue is generated from sales of its commercial products. This chart shows how investors view its current pipeline and the potential of its pipeline.
P/S market segment - Pharma git
RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company has commercial products and continues to develop new treatments, creating a diversified model. This chart reflects the average revenue estimate for the sector, which helps assess the market's perception of RedHill's product portfolio.
P/S of the market as a whole
RedHill Biopharma is an Israeli biopharmaceutical company specializing in drugs for the treatment of gastrointestinal diseases and infections. This graph, showing average revenue estimates, helps assess market sentiment for the company, which has a diversified portfolio of approved and developing products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal treatments. It has both commercial products and pipeline candidates. Estimating future revenue is important to the company. It reflects investor expectations for sales growth of its existing products and the success of its clinical programs in the future.
%20P%2FS%20RedHill%20Biopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-RedHill-Biopharma&v=1772513838306 "The graph of the company's future (projected) P/S RedHill Biopharma")
Future (projected) P/S of the market segment - Pharma git
RedHill Biopharma is a biopharmaceutical company specializing in gastrointestinal and infectious diseases. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the commercial success of its existing drugs and the potential of its late-stage pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772513838357 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
RedHill Biopharma is an Israeli biopharmaceutical company specializing in therapeutics for the treatment of gastrointestinal and infectious diseases. The company has both commercial products and clinical development pipelines. This graph of investor expectations reflects their view of the pharmaceutical sector and its revenue generation potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513838380 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales RedHill Biopharma
This chart shows RedHill Biopharma's revenue generated from sales of its commercial gastrointestinal medications, such as Talicia and Movantik. Revenue growth reflects the successful promotion of these products among physicians and their increasing market share.
Sales of companies in the market segment - Pharma git
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. Its sales breakdown shows which of its commercial drugs (Talicia, Movantik) contributes the most to revenue, demonstrating its successful transition from development to commercialization.
Overall market sales
RedHill Biopharma is a specialty pharmaceutical company focused on gastrointestinal diseases. Demand for its products is driven by medical needs. This overall market performance chart has no direct impact on the company, which operates in the non-cyclical healthcare sector, where treatment efficacy and safety are paramount.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company RedHill Biopharma
RedHill Biopharma is a specialty biopharmaceutical company focused on treating gastrointestinal diseases. Revenue growth depends on sales of its commercial products and the success of its clinical development. This chart shows analysts' expectations for demand for its drugs, such as Talicia for the treatment of H. pylori infection.
%20sales%20of%20the%20company%20RedHill%20Biopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-RedHill-Biopharma&v=1772513838466 "Schedule of future (projected) sales of the company RedHill Biopharma")
Future (projected) sales of companies in the market segment - Pharma git
RedHill Biopharma specializes in gastrointestinal medications. This chart shows the forecast for the gastrointestinal drug market. Is the need for new treatments for conditions such as H. pylori infection and Crohn's disease growing? This reflects the overall trend in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772513838474 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
RedHill Biopharma is a specialty pharmaceutical company focused on gastrointestinal diseases. The need for treatments for these conditions is generally stable and unaffected by economic cycles. This graph, reflecting overall consumer spending, has minimal impact on demand for the company's products, which is driven by medical prescriptions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513838476 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality RedHill Biopharma
RedHill Biopharma is an Israeli biopharmaceutical company specializing in drugs for the treatment of gastrointestinal diseases and infections. This chart shows its financial trajectory during the commercialization phase of its products. Profitability depends on sales volumes of approved drugs and the success of its clinical programs targeting significant markets.
Market segment marginality - Pharma git
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. The company's profitability depends on sales of its commercial products and the success of its clinical programs. This metric reflects how the company balances commercial activities with R&D investments to achieve profitability.
Market marginality as a whole
RedHill Biopharma is a specialty pharmaceutical company focused on gastrointestinal diseases. Its success depends on sales of commercialized drugs. This overall profitability chart reflects the state of the healthcare system, which influences drug pricing and prescription volumes.
Employees in the company, segment and market as a whole
Number of employees in the company RedHill Biopharma
RedHill Biopharma is an Israeli pharmaceutical company with a portfolio of commercial products for the treatment of gastrointestinal diseases and infections. Its staff includes a commercial team and an R&D department. This chart shows how the company balances advancing existing products with investing in the development of new drugs for future growth.
Share of the company's employees RedHill Biopharma within the market segment - Pharma git
RedHill Biopharma is a pharmaceutical company commercializing drugs for the treatment of gastrointestinal diseases. Unlike R&D startups, a commercial company requires a large staff of sales and marketing specialists. This graph shows the company's market share, reflecting the scale of its commercial infrastructure.
Number of employees in the market segment - Pharma git
RedHill Biopharma is an Israeli biopharmaceutical company specializing in the treatment of gastrointestinal and infectious diseases. The chart illustrates its work in this area. The company has several commercialized products, which distinguishes it from many biotech companies in the development stage.
Number of employees in the market as a whole
RedHill Biopharma is a specialized biopharmaceutical company focused on gastrointestinal diseases. Its HR policy is determined by the development and commercialization stages of its drugs. Against the backdrop of the overall labor market dynamics illustrated by this chart, RedHill represents a niche healthcare segment with its own specific growth characteristics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company RedHill Biopharma (RDHL)
RedHill Biopharma is an Israeli biopharmaceutical company focused on the gastrointestinal tract. They have commercial products (Talicia, Movantik). This chart shows how the market values their hybrid model. It reflects the market value per employee, balancing the value of their R&D pipeline with the effectiveness of their commercial (sales) team.
%20of%20the%20company%20RedHill%20Biopharma%20(RDHL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-RedHill-Biopharma-RDHL&v=1772513838668 "Chart of market capitalization per employee (in thousands of dollars) of the company RedHill Biopharma (RDHL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
RedHill Biopharma (RDHL) is a biopharmaceutical company specializing in gastrointestinal diseases and infections. This pharmaceutical chart reflects the value of its commercial products and development pipeline. Changes in this indicator may be due to increased sales of approved drugs or the successful progress of new candidates in clinical trials.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772513838708 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. Its value is determined by its portfolio of commercialized products and developments. The chart shows how the market perceives the sales potential of these products and the effectiveness of its commercial team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513838737 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company RedHill Biopharma (RDHL)
RedHill Biopharma is an Israeli pharmaceutical company specializing in gastrointestinal diseases. The company has commercially available drugs. This chart shows how successfully the company is monetizing its portfolio. It reflects how much net profit the team (R&D, sales) generates from the sale of its approved drugs.
%20Chart%20RedHill%20Biopharma%20(RDHL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-RedHill-Biopharma-RDHL&v=1772513838755 "Company Profit Per Employee (in thousands of dollars) Chart RedHill Biopharma (RDHL)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
RedHill Biopharma Ltd. is an Israeli biopharmaceutical company specializing in gastrointestinal therapeutics. Employee performance in this area depends on the successful commercialization of approved drugs. The graph shows the team's revenue generation, a key indicator of the success of their product portfolio.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772513838769 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
RedHill Biopharma is an Israeli pharmaceutical company focused on gastrointestinal diseases. They have both commercial products (Talicia, Movantik) and R&D. They operate a hybrid of R&D and sales. This chart helps understand how a specialized pharmaceutical company with an in-house sales force compares in terms of staff efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513838798 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee RedHill Biopharma (RDHL)
RedHill Biopharma is a pharmaceutical company specializing in gastrointestinal diseases. This chart is an indicator of the commercial success of their drugs. The increase in revenue per employee reflects increased sales, successful marketing, and the recognition of their drugs by the medical community for the treatment of common conditions.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-RedHill-Biopharma-RDHL&v=1772513838813 "Sales chart per company employee RedHill Biopharma (RDHL)")
Sales per employee in the market segment - Pharma git
RedHill Biopharma (RDHL) is an Israeli biotech focused on gastrointestinal diseases. They have approved drugs (Talicia, Movantik). This chart shows the average sales volume in the sector. For RDHL, this is an indicator of how productive their commercial team is in selling these specialized drugs compared to their competitors.
Sales per employee for the market as a whole
RedHill Biopharma is a commercial-stage pharmaceutical company. They have a portfolio of drugs, primarily for the treatment of gastrointestinal diseases. This indicator demonstrates how effective their sales and marketing team is in promoting and selling their products in a competitive market.
Short shares by company, segment and market as a whole
Shares shorted by company RedHill Biopharma (RDHL)
RedHill (RDHL) is an Israeli biopharmaceutical company focused on gastrointestinal diseases. The company has commercial products but is losing money. This chart shows the number of short positions. Bears may doubt the potential for sales growth in its products or its ability to achieve profitability.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-RedHill-Biopharma-RDHL&v=1772513838886 "Short Shares Chart for the Company RedHill Biopharma (RDHL)")
Shares shorted by market segment - Pharma git
RedHill Biopharma (RDHL) is an Israeli pharmaceutical company specializing in gastrointestinal diseases (such as Talicia for H. pylori) and rare diseases. This chart shows the total short position in the specialty pharmaceuticals sector. It reflects investor concerns about competition and commercialization risks.
Shares shorted by the overall market
RedHill Biopharma is a pharmaceutical company focused on gastrointestinal tract and infections. It has approved, but not very successful, drugs. This chart illustrates the overall market pessimism. Investors see the company as heavily indebted and doubt it will be able to increase sales and refinance its debt during the crisis.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator RedHill Biopharma (RDHL)
RedHill Biopharma specializes in the treatment of gastrointestinal diseases (e.g., H. pylori, Crohn's disease). It is a commercial company with R&D. This chart tracks the "pulse" of their sales and development. It "warms" on reports of revenue growth from existing drugs or the success of new trials.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-RedHill-Biopharma-RDHL&v=1772513838942 "RSI 14 indicator chart for the company's stock RedHill Biopharma (RDHL)")
RSI 14 Market Segment - Pharma git
RedHill Biopharma (RDHL) is an Israeli pharmaceutical company specializing in gastrointestinal diseases. They have also developed a drug (Opaganib) with antiviral potential. This chart tracks the overall sentiment in the Pharma/GI sector. It helps investors understand whether RDHL's performance reflects their pipeline or whether the overall biotech sector is overheated or oversold.
RSI 14 for the overall market
For RedHill Biopharma (RDHL), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash spigot is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RDHL (RedHill Biopharma)
RedHill Biopharma is an Israeli company focused on the gastrointestinal tract. Its key commercial drugs are Talicia (for the treatment of H. pylori infection) and Movantik (for constipation). This chart shows the average analyst price target, which is almost entirely dependent on their sales growth forecasts for these two drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RDHL-RedHill-Biopharma&v=1772513838999 "A chart showing analyst consensus forecasts for the expected stock price. RDHL (RedHill Biopharma)")
The difference between the consensus estimate and the actual stock price RDHL (RedHill Biopharma)
RedHill is an Israeli biopharmaceutical company focused on gastrointestinal diseases. Their portfolio includes Talicia (an H. pylori treatment) and Movantik (an opioid constipation treatment). This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the commercial success of their drugs and their R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RDHL-RedHill-Biopharma&v=1772513839039 "A chart showing the difference between the consensus forecast and the actual stock price. RDHL (RedHill Biopharma)")
Analyst consensus forecast for stock prices by market segment - Pharma git
RedHill Biopharma (RDHL) is an Israeli biotech company focused on gastrointestinal (GI) drugs (Talicia for H. pylori, Movantik for constipation). This chart shows analysts' overall expectations for the GI pharmaceutical sector. It reflects whether experts believe these drugs will be commercially successful in a competitive market.
Analysts' consensus forecast for the overall market share price
RedHill Biopharma is an Israeli biotech company specializing in gastrointestinal treatments (Talicia for H. pylori, Movantik). This chart shows overall market sentiment. For RedHill, which operates in the "defensive" healthcare sector, overall optimism is important for funding, but their growth depends more on successful marketing of niche products.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index RedHill Biopharma
RedHill Biopharma is an Israeli specialty pharmaceutical company. Their specialty is the commercialization of niche gastrointestinal (GI) drugs, specifically Talicia (for H. pylori) and Movantik (an opioid constipation treatment). This chart summarizes their commercialization history. It reflects their (slow) sales growth, their cash burn (on marketing), and their (high) debt.
AKIMA Market Segment Index - Pharma git
RedHill Biopharma (RDHL) is an Israeli pharmaceutical company focused on the gastrointestinal tract. Their business is dual: they have commercial drugs (Talicia for the treatment of H. pylori and Movantik for constipation) and an R&D pipeline for Crohn's disease and gastrointestinal cancer. This chart shows the average index for the segment, which helps assess the success of this hybrid commercial model.
The AKIM Index for the overall market
RedHill Biopharma is an Israeli biopharmaceutical company specializing in gastrointestinal and infectious diseases (Talicia, Movantik). This chart, which reflects the market average, provides a macro backdrop. It helps assess how RDHL, a commercial company with a product portfolio, compares to overall economic trends.
